Does Amerigroup Cover Trulicity?

How Amerigroup Classifies Trulicity on Its Formulary

Amerigroup operates as a Medicaid managed care organization under Elevance Health (formerly Anthem Inc.) across more than 20 states. Each state contract produces a separate preferred drug list (PDL), meaning Trulicity's tier placement is not uniform across Amerigroup's national footprint. In states where the Medicaid fee-for-service PDL includes dulaglutide as a preferred agent, the Amerigroup managed care plan generally mirrors that placement. In states where another GLP-1 (often semaglutide or liraglutide) holds preferred status, Trulicity may sit on a non-preferred brand tier with additional utilization management.

Preferred vs. Non-Preferred Tier Placement

On a preferred brand tier, Trulicity requires standard prior authorization but no additional step-therapy beyond metformin. On a non-preferred tier, the plan may require documented failure or intolerance of the preferred GLP-1 agent before it will approve dulaglutide. The practical difference: a preferred-tier approval might take 24 to 72 hours, while a non-preferred approval can stretch past a week if clinical documentation needs supplementation.

Why Tier Status Changes Year to Year

State Medicaid programs renegotiate supplemental rebate agreements with manufacturers annually. Eli Lilly's rebate competitiveness against Novo Nordisk (which markets Ozempic and Victoza) determines whether Trulicity holds preferred status in any given contract year. A drug that was preferred in your state last year may not be preferred now. The most reliable check is your state's current Amerigroup formulary document, typically posted as a PDF on the Amerigroup member portal.

Prior Authorization Requirements for Trulicity Under Amerigroup

Amerigroup requires prior authorization (PA) for Trulicity in virtually every state plan. The PA process confirms that the prescription meets medical necessity criteria before the plan pays for the medication. Your prescriber's office handles the submission, but understanding the criteria helps you anticipate what documentation is needed.

Standard Criteria Across Most States

The typical Amerigroup PA for dulaglutide requires all of the following: a confirmed diagnosis of type 2 diabetes with an HbA1c at or above 7.0%, a documented trial of metformin (usually 90 days at maximum tolerated dose) or a medical contraindication to metformin such as an eGFR below 30 mL/min/1.73 m², and prescribing by or in consultation with an endocrinologist or a primary care provider managing diabetes. Some states add a requirement for documented failure of a sulfonylurea or a DPP-4 inhibitor before GLP-1 therapy.

How Long Approval Takes

Initial PA decisions are due within 24 hours for urgent requests and 72 hours for standard requests under federal Medicaid timelines. If Amerigroup denies the PA, the prescriber can submit a peer-to-peer review or a formal appeal. Denial rates for GLP-1 medications under Medicaid managed care plans run between 15% and 30% on initial submission, according to a 2023 analysis of Medicaid utilization management barriers. Most denials result from incomplete documentation rather than a true medical necessity dispute.

Expedited Requests

If your blood glucose is dangerously uncontrolled (HbA1c above 10% or recurrent hypoglycemia on current therapy), your prescriber can file an expedited PA. Amerigroup must respond within 24 hours. Attach the most recent lab panel and a brief clinical note explaining urgency.

What Trulicity Costs Under Amerigroup Medicaid

Medicaid beneficiaries pay substantially less out of pocket than commercially insured patients. The Medicaid Drug Rebate Program requires manufacturers to provide minimum rebates of 23.1% of average manufacturer price for branded drugs, with additional supplemental rebates negotiated at the state level.

Copay Structure

Federal rules cap Medicaid copays based on income. For most Amerigroup members, the copay for a preferred brand drug is $1 to $3 per fill. Non-preferred brands may carry a slightly higher copay in some states, but Medicaid cost-sharing cannot exceed 5% of household income. Trulicity's retail price without insurance runs approximately $994 per month for the 1.5 mg dose pen, so the Medicaid benefit eliminates more than 99% of the cost.

When You Owe Nothing

Members with incomes below 100% of the federal poverty level, pregnant women, children under 18, and individuals in institutional care are exempt from all Medicaid copays. If you fall into one of these categories, your Trulicity cost is $0 regardless of tier placement.

Step Therapy: What You Must Try Before Trulicity

Step therapy (sometimes called "fail first") is the most common barrier to GLP-1 access under Amerigroup. The rationale is cost efficiency: metformin costs roughly $4 per month versus Trulicity's list price near $1,000.

The Metformin Step

The American Diabetes Association Standards of Care recommend metformin as first-line pharmacotherapy for most adults with type 2 diabetes unless contraindicated. Amerigroup's step-therapy protocols align with this guideline. You need to show at least 90 days of metformin use at 1,500 to 2,000 mg daily (or maximum tolerated dose) with an HbA1c that remains above target.

Bypassing Step Therapy

Three scenarios allow your prescriber to skip the metformin step. First, a documented contraindication: stage 4 or 5 chronic kidney disease (eGFR below 30), history of lactic acidosis, or severe gastrointestinal intolerance confirmed in the medical record. Second, established atherosclerotic cardiovascular disease (ASCVD), where GLP-1 receptor agonists with proven cardiovascular benefit carry a Class I recommendation from the ADA independent of HbA1c. Third, a clinical scenario where HbA1c exceeds 10% at diagnosis, making dual therapy a reasonable starting point.

The REWIND Trial and Cardiovascular Justification

The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced the composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 12% (HR 0.88, 95% CI 0.79-0.99) over a median 5.4 years. This trial is particularly relevant for Amerigroup PA appeals because REWIND enrolled patients at lower cardiovascular risk than most GLP-1 cardiovascular outcomes trials. Dr. Hertzel Gerstein, the REWIND principal investigator, noted: "Dulaglutide reduced cardiovascular events in a broad population of people with type 2 diabetes, including those without prior cardiovascular disease." This positions Trulicity for broader coverage arguments than GLP-1s studied only in high-risk populations.

What Happens If Amerigroup Denies Trulicity Coverage

A denial is not the end of the process. Medicaid managed care plans must offer a formal appeals pathway, and external review options exist beyond the plan level.

Internal Appeal

Your prescriber submits additional clinical documentation supporting medical necessity. Common additions include trend HbA1c values showing inadequate control on current therapy, documentation of metformin side effects, or cardiovascular risk factors that warrant a GLP-1 with proven CV benefit. Amerigroup must decide the internal appeal within 30 days for standard requests. A 2021 KFF analysis found that roughly 40% to 60% of initial GLP-1 denials are overturned on internal appeal when prescribers provide complete clinical justification.

State Fair Hearing

If the internal appeal fails, every Medicaid beneficiary has the right to a state fair hearing. This is an independent review outside of Amerigroup's internal process. The hearing examiner evaluates whether the denial followed state Medicaid coverage rules. Fair hearings have higher overturn rates than internal appeals for medications with strong guideline support.

Manufacturer Assistance During the Wait

Eli Lilly offers the Lilly Diabetes Solution Center, which may provide temporary free medication while PA or appeals are pending. Eligibility varies, and this resource does not replace insurance coverage long-term, but it can prevent treatment gaps during the authorization process.

Trulicity Dosing Covered by Amerigroup

Amerigroup covers all four FDA-approved dulaglutide doses: 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg, each administered once weekly by subcutaneous injection. The prescribing information recommends starting at 0.75 mg weekly for four weeks, then increasing to 1.5 mg weekly.

Higher Doses and PA Implications

The 3 mg and 4.5 mg doses received FDA approval in 2020 based on the AWARD-11 trial (N=1,842), which showed that 4.5 mg dulaglutide reduced HbA1c by 1.87% at 36 weeks, compared to 1.64% with 1.5 mg. Some Amerigroup plans require a separate PA or dose-escalation justification for the 3 mg and 4.5 mg pens. The justification typically requires documentation of inadequate glycemic control (HbA1c above 7.0%) after at least 12 weeks on the 1.5 mg dose.

Switching From Other GLP-1 Agents

If you are switching to Trulicity from another GLP-1 (for example, due to formulary changes), Amerigroup generally approves the transition without repeating step therapy, provided your previous GLP-1 was authorized through the plan. Your prescriber should reference the prior authorization number for the previous GLP-1 in the new PA request.

How Trulicity Compares to Other GLP-1s on Amerigroup Formularies

Amerigroup's preferred GLP-1 varies by state, but the most common alternatives on the formulary include Ozempic (semaglutide), Victoza (liraglutide), and Byetta (exenatide). Understanding how Trulicity compares helps you and your prescriber build a case if Trulicity is non-preferred in your state.

Efficacy Comparisons

The SUSTAIN-7 trial (N=1,201) compared semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg. Semaglutide 1.0 mg reduced HbA1c by 1.8% versus 1.4% for dulaglutide 1.5 mg at 40 weeks. Weight loss favored semaglutide as well: 6.5 kg versus 3.0 kg. These differences explain why some state Medicaid programs prefer semaglutide on their formularies.

When Trulicity May Be Clinically Preferable

Trulicity's broader cardiovascular evidence base (REWIND enrolled lower-risk patients than SUSTAIN-6) and its simpler dose-titration schedule make it a reasonable choice for patients who do not tolerate semaglutide's gastrointestinal side effects or who have lower baseline cardiovascular risk. Some patients also prefer Trulicity's pen design, which hides the needle and requires no manual attachment. These clinical justifications can support a PA for Trulicity even when another GLP-1 is preferred.

How to Check Your Specific Amerigroup Formulary

Coverage details change quarterly. The fastest way to verify Trulicity's current status on your plan is to follow these steps.

Online Formulary Lookup

Log into the Amerigroup member portal for your state (the URL format is typically amerigroup.com/[state-abbreviation]). Manage to "Pharmacy" or "Find a Drug" and search for dulaglutide. The result will show tier placement, PA requirements, quantity limits, and any step-therapy prerequisites specific to your state plan.

Call Member Services

If the online tool is unclear, call the number on the back of your Amerigroup card. Ask specifically: "Is dulaglutide on my preferred drug list, and what prior authorization criteria apply?" Request the PA criteria document by fax or mail so your prescriber has the exact requirements.

Ask Your Prescriber's Office

Most endocrinology and primary care offices that regularly prescribe GLP-1 medications have staff dedicated to insurance authorizations. They often know from experience which Amerigroup state plans prefer Trulicity and which prefer a competitor, saving you the research step.

Timeline From Prescription to First Injection

Knowing the realistic timeline helps you plan and avoid treatment gaps. For most Amerigroup members, the process from initial prescription to first dose takes 5 to 14 days.

Day 1 to 3: PA Submission

Your prescriber submits the prior authorization with supporting documentation: diagnosis, HbA1c values, medication history, and any relevant contraindications to first-line agents.

Day 3 to 7: PA Decision

Amerigroup reviews and issues a decision. If approved, the authorization is sent electronically to your pharmacy. If denied, your prescriber receives a denial letter with the specific reason and instructions for appeal.

Day 7 to 14: Pharmacy Fill

Once approved, your pharmacy orders the medication (specialty pharmacies may require 2 to 5 business days for delivery). Some Amerigroup plans require use of a preferred specialty pharmacy. Confirm with your plan whether your local retail pharmacy can fill the prescription or whether it must go through a designated specialty pharmacy.

The first self-administered injection should be supervised or preceded by injection training. Trulicity's single-dose pen is designed for ease of use, but a brief demonstration from a pharmacist or nurse reduces the chance of administration errors.